Verastem (VSTM) Stock Forecast & Price Target

Verastem is supported by a newly approved Avmapki Fakzynja launch that delivered $24.0M in net product revenue in 3Q26, up 114% year over year, with strong refill growth suggesting improving persistence even as new patient starts were seasonally softer. Its outlook is further strengthened by a differentiated RAF/MEK plus FAK biology, a $172.8M cash balance and $422.8M pro forma liquidity that management expects to fund operations into 1H28, and a G12D program that could generate over $2B across indications if partnered and successfully advanced. Although R&D rose to $68.8M and competition is intense, the combination of commercial traction, multiple 2027 data catalysts, and encouraging efficacy and tolerability signals supports a constructive fundamental view.

Verastem is viewed cautiously because its lead program, Avmapki Fakzynja, lacks sizable and definitive randomized data, leaving commercial traction, durability, and safety unproven in a small LGSOC market. The company also faces meaningful execution risk if RAMP-301 disappoints, since failure could sharply reduce intrinsic value and leave shares near net cash with minimal pipeline contribution, around $3/share in the downside case. Beyond the lead asset, competitive pressure may hinder enrollment and uptake, while most expansion opportunities, including G12D, remain early stage and still lack proof of concept data.